{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:07:20Z","timestamp":1788862040930,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01465-5","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:07:14Z","timestamp":1788858434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Top 10 Concepts in Secondary ASCVD Prevention From the 2026 ACC\/AHA Dyslipidemia Guideline: What Is New and Why It Matters"],"prefix":"10.1007","volume":"28","author":[{"given":"Ahmed Kamal","family":"Siddiqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerril","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandita","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"1465_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000659","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association. Circulation. 2019. https:\/\/doi.org\/10.1161\/CIR.0000000000000659.","journal-title":"Circulation"},{"issue":"8","key":"1465_CR2","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.cjca.2024.04.017","volume":"40","author":"LR Brunham","year":"2024","unstructured":"Brunham LR, Lonn E, Mehta SR. Dyslipidemia and the Current State of Cardiovascular Disease: Epidemiology, Risk Factors, and Effect of Lipid Lowering. Can J Cardiol. 2024;40(8):S4\u201312. https:\/\/doi.org\/10.1016\/j.cjca.2024.04.017.","journal-title":"Can J Cardiol"},{"key":"1465_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000624","author":"SM Grundy","year":"2018","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018. https:\/\/doi.org\/10.1161\/CIR.0000000000000624.","journal-title":"Circulation"},{"issue":"16","key":"1465_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMra1806939","volume":"381","author":"ED Michos","year":"2019","unstructured":"Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381(16):1557\u201367. https:\/\/doi.org\/10.1056\/NEJMra1806939.","journal-title":"N Engl J Med"},{"issue":"1","key":"1465_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"9493","key":"1465_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"Efficacy","year":"2005","unstructured":"Efficacy. safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(05)67394-1.","journal-title":"Lancet"},{"issue":"4","key":"1465_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.045376","volume":"15","author":"H Zheng","year":"2026","unstructured":"Zheng H, Chen G, Huo Z, Lan Y, Wang Y, Fu P, et al. Remnant cholesterol and atherosclerotic cardiovascular disease risk in populations with different low-density lipoprotein cholesterol elevations: a prospective cohort study. J Am Heart Assoc. 2026;15(4):e045376. https:\/\/doi.org\/10.1161\/JAHA.125.045376.","journal-title":"J Am Heart Assoc"},{"key":"1465_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1264319","volume":"10","author":"E Reijnders","year":"2023","unstructured":"Reijnders E, Van Der Laarse A, Jukema JW, Cobbaert CM. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine. Front Cardiovasc Med. 2023;10:1264319. https:\/\/doi.org\/10.3389\/fcvm.2023.1264319.","journal-title":"Front Cardiovasc Med"},{"issue":"15","key":"1465_CR9","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504. https:\/\/doi.org\/10.1056\/NEJMoa040583.","journal-title":"N Engl J Med"},{"issue":"14","key":"1465_CR10","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa050461.","journal-title":"N Engl J Med"},{"issue":"19","key":"1465_CR11","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction The IDEAL Study: A Randomized Controlled Trial. JAMA. 2005;294(19):2437. https:\/\/doi.org\/10.1001\/jama.294.19.2437.","journal-title":"JAMA"},{"issue":"1","key":"1465_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","volume":"14","author":"UK Sampson","year":"2012","unstructured":"Sampson UK, Fazio S, Linton MF. Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Curr Atheroscler Rep. 2012;14(1):1\u201310. https:\/\/doi.org\/10.1007\/s11883-011-0219-7.","journal-title":"Curr Atheroscler Rep"},{"key":"1465_CR13","doi-asserted-by":"publisher","unstructured":"Writing Committee Members, Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 153 2026;CIR.0000000000001423. https:\/\/doi.org\/10.1161\/CIR.0000000000001423.","DOI":"10.1161\/CIR.0000000000001423"},{"issue":"3","key":"1465_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10557-018-6800-3","volume":"32","author":"SH Boklage","year":"2018","unstructured":"Boklage SH, Malangone-Monaco E, Lopez-Gonzalez L, Ding Y, Henriques C, Elassal J. Statin utilization patterns and outcomes for patients with acute coronary syndrome during and following inpatient admissions. Cardiovasc Drugs Ther. 2018;32(3):273\u201380. https:\/\/doi.org\/10.1007\/s10557-018-6800-3.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"1465_CR15","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","volume":"46","author":"KK Ray","year":"2005","unstructured":"Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2005;46(8):1405\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2005.03.077.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1465_CR16","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/jcm15031075","volume":"15","author":"M Vatri","year":"2026","unstructured":"Vatri M, Faggiano A, Angelino E, Ambrosetti M, Faggiano PM, Fattirolli F. Therapeutic Inertia in Lipid-Lowering Treatment: A Narrative Review. J Clin Med. 2026;15(3):1075. https:\/\/doi.org\/10.3390\/jcm15031075.","journal-title":"J Clin Med"},{"issue":"8","key":"1465_CR17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","volume":"134","author":"J Underberg","year":"2022","unstructured":"Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med. 2022;134(8):752\u201362. https:\/\/doi.org\/10.1080\/00325481.2022.2117498.","journal-title":"Postgrad Med"},{"issue":"10","key":"1465_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","volume":"21","author":"BA Ference","year":"2024","unstructured":"Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis: evidence and practical applications. Nat Rev Cardiol. 2024;21(10):701\u201316. https:\/\/doi.org\/10.1038\/s41569-024-01039-5.","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"1465_CR19","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/archinte.166.17.1814","volume":"166","author":"E Hulten","year":"2006","unstructured":"Hulten E, Jackson JL, Douglas K, George S, Villines TC. The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials. Arch Intern Med. 2006;166(17):1814. https:\/\/doi.org\/10.1001\/archinte.166.17.1814.","journal-title":"Arch Intern Med"},{"key":"1465_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625","author":"SM Grundy","year":"2018","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","journal-title":"Circulation"},{"issue":"1","key":"1465_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jacl.2025.11.010","volume":"20","author":"A Faggiano","year":"2026","unstructured":"Faggiano A, Maloberti A, Ambrosetti M, Giallauria F, Mureddu G, Venturini E, et al. From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: A Monte Carlo simulation within the ITACARE-P registry. J Clin Lipidol. 2026;20(1):21\u201330. https:\/\/doi.org\/10.1016\/j.jacl.2025.11.010.","journal-title":"J Clin Lipidol"},{"issue":"9753","key":"1465_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","journal-title":"Lancet"},{"key":"1465_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.118540","volume":"396","author":"PM Burger","year":"2024","unstructured":"Burger PM, Dorresteijn JAN, Koudstaal S, Holtrop J, Kastelein JJP, Jukema JW, et al. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 60 randomized controlled trials. Atherosclerosis. 2024;396:118540. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118540.","journal-title":"Atherosclerosis"},{"issue":"22","key":"1465_CR24","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"18","key":"1465_CR25","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"12","key":"1465_CR26","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287. https:\/\/doi.org\/10.1001\/jamacardio.2019.3780.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"1465_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.113.005873","volume":"129","author":"S Mora","year":"2014","unstructured":"Mora S, Buring JE, Ridker PM. Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events. Circulation. 2014;129(5):553\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005873.","journal-title":"Circulation"},{"issue":"4","key":"1465_CR28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","volume":"53","author":"JG Robinson","year":"2009","unstructured":"Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non\u2013high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53(4):316\u201322. https:\/\/doi.org\/10.1016\/j.jacc.2008.10.024.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1465_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/archinte.161.11.1413","volume":"161","author":"Y Cui","year":"2001","unstructured":"Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, et al. Non\u2013High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality. Arch Intern Med. 2001;161(11):1413. https:\/\/doi.org\/10.1001\/archinte.161.11.1413.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1465_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","volume":"4","author":"AD Sniderman","year":"2011","unstructured":"Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, De Graaf J, et al. A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337\u201345. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.110.959247.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"1465_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","volume":"7","author":"NA Marston","year":"2022","unstructured":"Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, et al. Association of Apolipoprotein B\u2013Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022;7(3):250. https:\/\/doi.org\/10.1001\/jamacardio.2021.5083.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"1465_CR32","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","volume":"77","author":"CDL Johannesen","year":"2021","unstructured":"Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77(11):1439\u201350. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.027.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1465_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamacardio.2024.1310","volume":"9","author":"A Sayed","year":"2024","unstructured":"Sayed A, Peterson ED, Virani SS, Sniderman AD, Navar AM. Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non\u2013HDL-C Levels. JAMA Cardiol. 2024;9(8):741. https:\/\/doi.org\/10.1001\/jamacardio.2024.1310.","journal-title":"JAMA Cardiol"},{"issue":"27","key":"1465_CR34","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","volume":"45","author":"AD Sniderman","year":"2024","unstructured":"Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Discordance among apoB, non\u2013high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J. 2024;45(27):2410\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehae258.","journal-title":"Eur Heart J"},{"issue":"10","key":"1465_CR35","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1177\/2047487315569411","volume":"22","author":"MJ Pencina","year":"2015","unstructured":"Pencina MJ, D\u2019Agostino RB, Zdrojewski T, Williams K, Thanassoulis G, Furberg CD, et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol. 2015;22(10):1321\u20137. https:\/\/doi.org\/10.1177\/2047487315569411.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"1465_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","volume":"41","author":"AP Patel","year":"2021","unstructured":"Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol. 2021;41(1):465\u201374. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315291.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1465_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","volume":"129","author":"AV Khera","year":"2014","unstructured":"Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: An analysis from the JUPITER trial. Circulation. 2014;129:635\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.004406.","journal-title":"Circulation"},{"issue":"10155","key":"1465_CR38","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","volume":"392","author":"P Willeit","year":"2018","unstructured":"Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(18)31652-0.","journal-title":"Lancet"},{"issue":"26","key":"1465_CR39","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. N Engl J Med. 2009;361(26):2518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa0902604.","journal-title":"N Engl J Med"},{"issue":"4","key":"1465_CR40","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"Lipoprotein(a)","year":"2009","unstructured":"Lipoprotein(a). Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA. 2009;302(4):412. https:\/\/doi.org\/10.1001\/jama.2009.1063.","journal-title":"JAMA"},{"issue":"12","key":"1465_CR41","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial. Circulation. 2019;139(12):1483\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184.","journal-title":"Circulation"},{"issue":"2","key":"1465_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.057.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1465_CR43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.122.009787","volume":"16","author":"AM Navar","year":"2023","unstructured":"Navar AM, Kolkailah AA, Gupta A, Gillard KK, Israel MK, Wang Y, et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322 153 patients. Circ Cardiovasc Qual Outcomes. 2023;16(8):533\u201343. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.122.009787.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"12","key":"1465_CR44","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jacc.2020.11.079","volume":"77","author":"NS Nurmohamed","year":"2021","unstructured":"Nurmohamed NS, Navar AM, Kastelein JJP. New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B. J Am Coll Cardiol. 2021;77(12):1564\u201375. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.079.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1465_CR45","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","journal-title":"N Engl J Med"},{"issue":"18","key":"1465_CR46","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.3390\/jcm14186445","volume":"14","author":"DM Brie","year":"2025","unstructured":"Brie DM, Morno\u0219 C, Adam O, T\u00eerziu A, Brie AD. Dyslipidemia Treatment in Patients with Acute Coronary Syndrome: Is It Time to Move to Combination Therapy? J Clin Med. 2025;14(18):6445. https:\/\/doi.org\/10.3390\/jcm14186445.","journal-title":"J Clin Med"},{"issue":"14","key":"1465_CR47","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJMoa2600283","volume":"394","author":"YJ Lee","year":"2026","unstructured":"Lee YJ, Lee SJ, Kim JW, Lee SH, Kim GS, Park JH, et al. Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease. N Engl J Med. 2026;394(14):1365\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2600283.","journal-title":"N Engl J Med"},{"issue":"15","key":"1465_CR48","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","volume":"85","author":"M Leosdottir","year":"2025","unstructured":"Leosdottir M, Schubert J, Brandts J, Gustafsson S, Cars T, Sundstr\u00f6m J, et al. Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry. J Am Coll Cardiol. 2025;85(15):1550\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2025.02.007.","journal-title":"J Am Coll Cardiol"},{"key":"1465_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ahj.2024.10.009","volume":"279","author":"NP Shah","year":"2025","unstructured":"Shah NP, Mulder H, Lydon E, Chiswell K, Hu X, Lampron Z, et al. Real-world exploration of LDL-cholesterol management in patients with atherosclerotic cardiovascular disease. Am Heart J. 2025;279:50\u20138. https:\/\/doi.org\/10.1016\/j.ahj.2024.10.009.","journal-title":"Am Heart J"},{"key":"1465_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag087","author":"BG Nordestgaard","year":"2026","unstructured":"Nordestgaard BG, Hegele RA. Residual lipid risk in atherosclerotic cardiovascular disease. Eur Heart J. 2026. https:\/\/doi.org\/10.1093\/eurheartj\/ehag087. ehag087.","journal-title":"Eur Heart J"},{"issue":"47","key":"1465_CR51","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehab551.","journal-title":"Eur Heart J"},{"issue":"6","key":"1465_CR52","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1111\/dom.16335","volume":"27","author":"C Witt","year":"2025","unstructured":"Witt C, Renfroe LG, Lyons TS. Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review. Diabetes Obes Metab. 2025;27(6):2940\u201354. https:\/\/doi.org\/10.1111\/dom.16335.","journal-title":"Diabetes Obes Metab"},{"issue":"20","key":"1465_CR53","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606\u201335. https:\/\/doi.org\/10.1161\/CIR.0000000000001184.","journal-title":"Circulation"},{"issue":"16","key":"1465_CR54","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2023.02.034","volume":"81","author":"WA Malick","year":"2023","unstructured":"Malick WA, Waksman O, Do R, Koenig W, Pradhan AD, Stroes ESG, et al. Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies. JACC. 2023;81(16):1646\u201358. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.034.","journal-title":"JACC"},{"issue":"1","key":"1465_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"key":"1465_CR56","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"key":"1465_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117556","volume":"393","author":"T Doi","year":"2024","unstructured":"Doi T, Langsted A, Nordestgaard BG. Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial. Atherosclerosis. 2024;393:117556. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117556.","journal-title":"Atherosclerosis"},{"issue":"21","key":"1465_CR58","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387(21):1923\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2210645.","journal-title":"N Engl J Med"},{"issue":"12","key":"1465_CR59","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1007\/s11010-025-05379-9","volume":"480","author":"Z Xu","year":"2025","unstructured":"Xu Z, Yang S, Tan Y, Zhang Q, Wang H, Tao J, et al. Inflammation in cardiovascular-kidney-metabolic syndrome: key roles and underlying mechanisms\u2013a comprehensive review. Mol Cell Biochem. 2025;480(12):6039\u201375. https:\/\/doi.org\/10.1007\/s11010-025-05379-9.","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"1465_CR60","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00109-021-02037-7","volume":"99","author":"P D\u00fcsing","year":"2021","unstructured":"D\u00fcsing P, Zietzer A, Goody PR, Hosen MR, Kurts C, Nickenig G, et al. Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. J Mol Med. 2021;99(3):335\u201348. https:\/\/doi.org\/10.1007\/s00109-021-02037-7.","journal-title":"J Mol Med"},{"issue":"24","key":"1465_CR61","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2023;148(24):1982\u20132004. https:\/\/doi.org\/10.1161\/CIR.0000000000001191.","journal-title":"Circulation"},{"issue":"18","key":"1465_CR62","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.jacc.2022.02.046","volume":"79","author":"MD Kelsey","year":"2022","unstructured":"Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson ED, McGuire DK, et al. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. J Am Coll Cardiol. 2022;79(18):1849\u201357. https:\/\/doi.org\/10.1016\/j.jacc.2022.02.046.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1465_CR63","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1-127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01465-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01465-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01465-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:07:15Z","timestamp":1788858435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01465-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01465-5","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is based on previously conducted and published studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"88"}}